Etoposide, cisplatin–etoposide, methotrexate, actinomycin‐D as primary treatment for management of very‐high‐risk gestational trophoblastic neoplasia
- 29 July 2011
- journal article
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 115 (1), 37-39
- https://doi.org/10.1016/j.ijgo.2011.04.017
Abstract
To evaluate the efficacy of etoposide, cisplatin-etoposide, methotrexate, actinomycin-D (EP-EMA) chemotherapy as the frontline treatment for gestational trophoblastic neoplasia (GTN) patients with very high (≥ 12) FIGO prognostic scores. Nine patients with very-high-risk GTN were treated with EP-EMA at the Cancer Institute, Adyar, India, between January 1, 2001, and December 31, 2007. Salvage chemotherapy, adjuvant surgery, and radiotherapy were used when indicated. Clinical response, toxicity, and survival were analyzed separately. The median FIGO score was 15. Six (66.7%) patients had a complete clinical response, whereas progressive disease occurred for 3 (33.3%) women. None of the patients relapsed. This translated to an overall survival rate of 66.7% in the primary setting. All patients with liver-only metastases were survivors after treatment with EP-EMA. Grade 3 neutropenia was detected in 3 (33.3%) patients only. No life-threatening toxicity was observed after EP-EMA treatment. EP-EMA was highly effective for the primary management of very-high-risk GTN.Keywords
This publication has 12 references indexed in Scilit:
- Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)Annals Of Oncology, 2008
- EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patientsInternational Journal of Gynecologic Cancer, 2008
- Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP‐EMA) regimenInternational Journal of Gynecology & Obstetrics, 2007
- Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasiaInternational Journal of Gynecologic Cancer, 2006
- EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV)International Journal of Gynecologic Cancer, 2004
- Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy☆Gynecologic Oncology, 2003
- Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic TumorsJournal of Clinical Oncology, 2000
- EMACO in High Risk Gestational Trophoblast Disease ‐ The Australian ExperienceAustralian and New Zealand Journal of Obstetrics and Gynaecology, 1994
- EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)Gynecologic Oncology, 1988
- Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984)BJOG: An International Journal of Obstetrics and Gynaecology, 1986